These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 18413795)

  • 21. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.
    Parry D; Guzi T; Shanahan F; Davis N; Prabhavalkar D; Wiswell D; Seghezzi W; Paruch K; Dwyer MP; Doll R; Nomeir A; Windsor W; Fischmann T; Wang Y; Oft M; Chen T; Kirschmeier P; Lees EM
    Mol Cancer Ther; 2010 Aug; 9(8):2344-53. PubMed ID: 20663931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
    Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4.
    Soni R; O'Reilly T; Furet P; Muller L; Stephan C; Zumstein-Mecker S; Fretz H; Fabbro D; Chaudhuri B
    J Natl Cancer Inst; 2001 Mar; 93(6):436-46. PubMed ID: 11259469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Off-target immune cell toxicity caused by AG-012986, a pan-CDK inhibitor, is associated with inhibition of p38 MAPK phosphorylation.
    Lee DU; Jessen B
    J Biochem Mol Toxicol; 2012 Mar; 26(3):101-8. PubMed ID: 22095879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo.
    Hirai H; Takahashi-Suziki I; Shimomura T; Fukasawa K; Machida T; Takaki T; Kobayashi M; Eguchi T; Oki H; Arai T; Ichikawa K; Hasako S; Kodera T; Kawanishi N; Nakatsuru Y; Kotani H; Iwasawa Y
    Invest New Drugs; 2011 Aug; 29(4):534-43. PubMed ID: 20084424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent.
    Misra RN; Xiao HY; Kim KS; Lu S; Han WC; Barbosa SA; Hunt JT; Rawlins DB; Shan W; Ahmed SZ; Qian L; Chen BC; Zhao R; Bednarz MS; Kellar KA; Mulheron JG; Batorsky R; Roongta U; Kamath A; Marathe P; Ranadive SA; Sack JS; Tokarski JS; Pavletich NP; Lee FY; Webster KR; Kimball SD
    J Med Chem; 2004 Mar; 47(7):1719-28. PubMed ID: 15027863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.
    Hardwicke MA; Oleykowski CA; Plant R; Wang J; Liao Q; Moss K; Newlander K; Adams JL; Dhanak D; Yang J; Lai Z; Sutton D; Patrick D
    Mol Cancer Ther; 2009 Jul; 8(7):1808-17. PubMed ID: 19567821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models.
    Alzani R; Pedrini O; Albanese C; Ceruti R; Casolaro A; Patton V; Colotta F; Rambaldi A; Introna M; Pesenti E; Ciomei M; Golay J
    Exp Hematol; 2010 Apr; 38(4):259-269.e2. PubMed ID: 20167248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
    Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ
    PLoS One; 2017; 12(2):e0172315. PubMed ID: 28207834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tangeretin induces cell-cycle G1 arrest through inhibiting cyclin-dependent kinases 2 and 4 activities as well as elevating Cdk inhibitors p21 and p27 in human colorectal carcinoma cells.
    Pan MH; Chen WJ; Lin-Shiau SY; Ho CT; Lin JK
    Carcinogenesis; 2002 Oct; 23(10):1677-84. PubMed ID: 12376477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis.
    Jarry M; Lecointre C; Malleval C; Desrues L; Schouft MT; Lejoncour V; Liger F; Lyvinec G; Joseph B; Loaëc N; Meijer L; Honnorat J; Gandolfo P; Castel H
    Neuro Oncol; 2014 Nov; 16(11):1484-98. PubMed ID: 24891448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.
    Schonbrunn E; Betzi S; Alam R; Martin MP; Becker A; Han H; Francis R; Chakrasali R; Jakkaraj S; Kazi A; Sebti SM; Cubitt CL; Gebhard AW; Hazlehurst LA; Tash JS; Georg GI
    J Med Chem; 2013 May; 56(10):3768-82. PubMed ID: 23600925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
    Xie S; Jiang H; Zhai XW; Wei F; Wang SD; Ding J; Chen Y
    Acta Pharmacol Sin; 2016 Nov; 37(11):1481-1489. PubMed ID: 27569395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFbeta and causing cell cycle arrest.
    Yang L; Ostrowski J; Reczek P; Brown P
    Oncogene; 2001 Nov; 20(55):8025-35. PubMed ID: 11753686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
    Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.
    Fry DW; Harvey PJ; Keller PR; Elliott WL; Meade M; Trachet E; Albassam M; Zheng X; Leopold WR; Pryer NK; Toogood PL
    Mol Cancer Ther; 2004 Nov; 3(11):1427-38. PubMed ID: 15542782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
    Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
    FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
    Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Novel IκB Kinase β Inhibitor, IMD-0560, Has Potent Therapeutic Efficacy in Ovarian Cancer Xenograft Model Mice.
    Sawada I; Hashimoto K; Sawada K; Kinose Y; Nakamura K; Toda A; Nakatsuka E; Yoshimura A; Mabuchi S; Fujikawa T; Itai A; Kimura T
    Int J Gynecol Cancer; 2016 May; 26(4):610-8. PubMed ID: 26905334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
    Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
    Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.